title: Estimating the Economic Impact of Sorafenib in Treatment of Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Carcinoma (DTC) That is Refractory to Radioactive Iodine (RAI) Treatment.
authors.affiliation: Boston Health Economics, Inc., Waltham, MA, USA.
authors.forename: M
authors.initials: M
authors.lastname: Sussman
authors.affiliation: Boston Health Economics, Inc., Waltham, MA, USA.
authors.forename: M
authors.initials: M
authors.lastname: Munsell
authors.affiliation: Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ, USA.
authors.forename: A
authors.initials: A
authors.lastname: Valderrama
authors.affiliation: Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ, USA.
authors.forename: B S
authors.initials: BS
authors.lastname: Seal
authors.affiliation: Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ, USA.
authors.forename: L
authors.initials: L
authors.lastname: Wen